View in EDS

MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia.

Saved in:
Bibliographic Details
Title: MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia.
Authors: Kagawa, Yosuke1 (AUTHOR), Nosaki, Kaname1 (AUTHOR), Matsumoto, Shingo1 (AUTHOR), Kato, Terufumi2 (AUTHOR), Nakamura, Atushi3 (AUTHOR), Shingyoji, Masato4 (AUTHOR), Nishino, Kazumi5 (AUTHOR), Tabata, Eriko6 (AUTHOR), Furuya, Naoki7 (AUTHOR), Miyamoto, Shingo8 (AUTHOR), Sakakibara, Jun9 (AUTHOR), Nakao, Mika10 (AUTHOR), Daga, Haruko11 (AUTHOR), Sakai, Tetsuya1 (AUTHOR), Shibata, Yuji1 (AUTHOR), Izumi, Hiroki1 (AUTHOR), Udagawa, Hibiki1 (AUTHOR), Zenke, Yoshitaka1 (AUTHOR), Yoh, Kiyotaka1 (AUTHOR), Goto, Koichi1 (AUTHOR)
Source: Annals of Oncology. 2022 Supplement 6, Vol. 33, pS510-S510. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 158120156
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Kagawa%2C+Yosuke%22">Kagawa, Yosuke</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nosaki%2C+Kaname%22">Nosaki, Kaname</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Matsumoto%2C+Shingo%22">Matsumoto, Shingo</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kato%2C+Terufumi%22">Kato, Terufumi</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nakamura%2C+Atushi%22">Nakamura, Atushi</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shingyoji%2C+Masato%22">Shingyoji, Masato</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nishino%2C+Kazumi%22">Nishino, Kazumi</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tabata%2C+Eriko%22">Tabata, Eriko</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Furuya%2C+Naoki%22">Furuya, Naoki</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Miyamoto%2C+Shingo%22">Miyamoto, Shingo</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sakakibara%2C+Jun%22">Sakakibara, Jun</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nakao%2C+Mika%22">Nakao, Mika</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Daga%2C+Haruko%22">Daga, Haruko</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sakai%2C+Tetsuya%22">Sakai, Tetsuya</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shibata%2C+Yuji%22">Shibata, Yuji</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Izumi%2C+Hiroki%22">Izumi, Hiroki</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Udagawa%2C+Hibiki%22">Udagawa, Hibiki</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zenke%2C+Yoshitaka%22">Zenke, Yoshitaka</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yoh%2C+Kiyotaka%22">Yoh, Kiyotaka</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Goto%2C+Koichi%22">Goto, Koichi</searchLink><relatesTo>1</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2022 Supplement 6, Vol. 33, pS510-S510. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=158120156
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2022.05.214
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S510
    Titles:
      – TitleFull: MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kagawa, Yosuke
      – PersonEntity:
          Name:
            NameFull: Nosaki, Kaname
      – PersonEntity:
          Name:
            NameFull: Matsumoto, Shingo
      – PersonEntity:
          Name:
            NameFull: Kato, Terufumi
      – PersonEntity:
          Name:
            NameFull: Nakamura, Atushi
      – PersonEntity:
          Name:
            NameFull: Shingyoji, Masato
      – PersonEntity:
          Name:
            NameFull: Nishino, Kazumi
      – PersonEntity:
          Name:
            NameFull: Tabata, Eriko
      – PersonEntity:
          Name:
            NameFull: Furuya, Naoki
      – PersonEntity:
          Name:
            NameFull: Miyamoto, Shingo
      – PersonEntity:
          Name:
            NameFull: Sakakibara, Jun
      – PersonEntity:
          Name:
            NameFull: Nakao, Mika
      – PersonEntity:
          Name:
            NameFull: Daga, Haruko
      – PersonEntity:
          Name:
            NameFull: Sakai, Tetsuya
      – PersonEntity:
          Name:
            NameFull: Shibata, Yuji
      – PersonEntity:
          Name:
            NameFull: Izumi, Hiroki
      – PersonEntity:
          Name:
            NameFull: Udagawa, Hibiki
      – PersonEntity:
          Name:
            NameFull: Zenke, Yoshitaka
      – PersonEntity:
          Name:
            NameFull: Yoh, Kiyotaka
      – PersonEntity:
          Name:
            NameFull: Goto, Koichi
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 07
              Text: 2022 Supplement 6
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 33
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1